Pharvaris NV (NAS:PHVS)

$ 19.84 1.01 (5.36%) Market Cap: 1.02 Bil Enterprise Value: 703.79 Mil PE Ratio: 0 PB Ratio: 3.10 GF Score: 40/100

Pharvaris NV at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Pharvaris NV Top-line CHAPTER-1 Data Readout Transcript
Dec 06, 2023
Pharvaris NV at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Pharvaris NV at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Pharvaris NV at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Pharvaris NV at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
Pharvaris NV RAPIDe-1 Call Transcript
Dec 08, 2022
Pharvaris NV at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Pharvaris NV at Bank of America Healthcare Conference Transcript
May 12, 2022
Pharvaris NV at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Pharvaris NV at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 21, 2021
Pharvaris BV at Life Sciences Partners BioCapital Europe Conference (Virtual) Transcript
Mar 11, 2021

Pharvaris NV Top-line CHAPTER-1 Data Readout Transcript

Dec 06, 2023 / 01:00PM GMT

Release Date Price: $24.75 (+18.14%)

Transcript

Maggie Beller Pharvaris NV;Executive Director

Head of External and Internal Communications

Welcome to the top-line data announcement of CHAPTER-1, a Phase 2 clinical study of deucrictibant for the prophylactic treatment of hereditary angioedema. My name is Maggie Beller, Head of Communications at Pharvaris. Please note that today's webcast is being recorded, and the slides will be uploaded onto the Investors section of our corporate website immediately following this call.

Please note that the statement of our guests today are their own and not those of Pharvaris, and Pharvaris makes no representation as to the adequacy, fairness, accuracy, or completeness of the information in their comments.

In addition, our presentation today will include forward-looking statements, including, but not limited to, statements regarding to deucrictibant and its potential as well as our preclinical and clinical studies, regulatory interactions, and future plans. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.